Translate Bio Inc (TBIO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Translate Bio Inc (TBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10693
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Translate Bio Inc (Translate Bio), formerly RaNA Therapeutics Inc is a healthcare service provider that develops therapies which targets RNA within cells in the body to selectively activate protein expression. The company provides platform oligonucleotides (oligos) are molecules designed to target specific areas of RNA. Its platform uses two distinct approaches to activate RNA during transcription and post-transcription. Translate Bio provides target treatment areas such as spinal muscular atrophy and friedreich’s ataxia. It offers other target treatment areas such as musculoskeletal disease, inflammatory disease and liver disease. The company provides investment partners such as Atlas Venture, Monsanto, MS Ventures, Omega Funds, Partners Innovation Fund, Pfizer Venture Investments and SR One, among others. Translate Bio is headquartered in Lexington, Massachusetts, the US.

Translate Bio Inc (TBIO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Translate Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Translate Bio Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
RaNA Therapeutics Acquires MRT Platform from Shire 10
Translate Bio to Acquire mRNA Therapy Platform from Shire Human Genetic Therapies 11
Venture Financing 12
Translate Bio Raises USD51 Million in Venture Financing 12
RaNA Therapeutics Raises USD55 Million in series B Financing 13
RaNA Therapeutics Raises Additional US$18 Million In Series A Financing 14
Licensing Agreements 16
Sanofi Pasteur Enters into Licensing Agreement with Translate Bio 16
RaNA Therapeutics Enters Into Licensing Agreement With Santaris Pharma To Develop RNA-Targeted Medicines 17
Equity Offering 18
Translate Bio Raises USD121.6 Million in IPO 18
Translate Bio Raises USD42 Million in Private Placement of Preferred Shares 20
Translate Bio Inc – Key Competitors 21
Translate Bio Inc – Key Employees 22
Translate Bio Inc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
Nov 08, 2018: Translate Bio announces third quarter 2018 financial results and reviews recent highlights 24
Aug 09, 2018: Translate Bio announces second quarter 2018 financial results and highlights recent development and corporate achievements 26
Corporate Communications 28
May 23, 2018: Translate Bio Appoints John R. Schroer As Chief Financial Officer 28
Nov 06, 2017: Translate Bio Appoints Ann Barbier, M.D., Ph.D., as Chief Medical Officer 29
Oct 04, 2017: Translate Bio Names Daniella Beckman to Board of Directors 30
Product Approvals 31
Apr 12, 2018: Translate Bio Announces FDA Clearance to Proceed with Phase 1/2 Clinical Trial in Patients with Cystic Fibrosis (CF) 31
Other Significant Developments 32
Jun 27, 2017: RaNA Therapeutics Relaunches as Translate Bio to Advance RNA Therapeutics 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Translate Bio Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Translate Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Translate Bio Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
RaNA Therapeutics Acquires MRT Platform from Shire 10
Translate Bio to Acquire mRNA Therapy Platform from Shire Human Genetic Therapies 11
Translate Bio Raises USD51 Million in Venture Financing 12
RaNA Therapeutics Raises USD55 Million in series B Financing 13
RaNA Therapeutics Raises Additional US$18 Million In Series A Financing 14
Sanofi Pasteur Enters into Licensing Agreement with Translate Bio 16
RaNA Therapeutics Enters Into Licensing Agreement With Santaris Pharma To Develop RNA-Targeted Medicines 17
Translate Bio Raises USD121.6 Million in IPO 18
Translate Bio Raises USD42 Million in Private Placement of Preferred Shares 20
Translate Bio Inc, Key Competitors 21
Translate Bio Inc, Key Employees 22

List of Figures
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Translate Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Translate Bio Inc (TBIO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • JAFCO Co., Ltd.:企業のM&A・事業提携・投資動向
    JAFCO Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's JAFCO Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • AutoNation, Inc. (AN):企業の財務・戦略的SWOT分析
    AutoNation, Inc. (AN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Catalina Holdings (Bermuda) Ltd:企業のM&A・事業提携・投資動向
    Catalina Holdings (Bermuda) Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Catalina Holdings (Bermuda) Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Inter Parfums Inc (IPAR):企業の財務・戦略的SWOT分析
    Summary Inter Parfums Inc (Inter Parfums) is a consumer goods company that manufactures, develops, and markets fragrance and beauty care products. The company’s products include cosmetics, fragrances, personal care products, and fragrance related products. Its personal care products comprise cosmeti …
  • Cabela’S Inc:企業の戦略・SWOT・財務分析
    Cabela'S Inc - Strategy, SWOT and Corporate Finance Report Summary Cabela'S Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Knight Therapeutics Inc (GUD):医療機器:M&Aディール及び事業提携情報
    Summary Knight Therapeutics Inc (Knight Therapeutics) is a specialty pharmaceutical company focused on acquisition, licensing, marketing and distribution of prescription, consumer health products and medical devices. Its consumer health products are used in the treatment of metabolic diseases, derma …
  • MLM Biologics Inc:企業の製品パイプライン分析
    Summary MLM Biologics Inc (MLM Biologics) operates as a medical device company that provides optimum wound care management for patients and doctors. The company’s product includes bio-ConneKt Wound Matrix, a collagen-based wound dressing for chronic vascular ulcers, draining wounds, partial and full …
  • Commonwealth Bank of Australia:企業の戦略・SWOT・財務情報
    Commonwealth Bank of Australia - Strategy, SWOT and Corporate Finance Report Summary Commonwealth Bank of Australia - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Accu-Break Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Accu-Break Pharmaceuticals Inc (Accu-Break) is a developer and provider of pharmaceutical tablet technologies for accurate and customized dosing. The company provides services such as patented technologies, product differentiation, life cycle management, APIs solutions, product enhancement, …
  • DPL Inc. (DPL):電力:M&Aディール及び事業提携情報
    Summary DPL Inc. (DPL) a subsidiary of AES Corporation is a diversified energy and utility company. It is engaged in the generation, transmission and distribution of electricity in West Central Ohio. The company provides its services to residential, commercial, and industrial and government customer …
  • PT Tigaraksa Satria Tbk (TGKA):企業の財務・戦略的SWOT分析
    PT Tigaraksa Satria Tbk (TGKA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Ross Offshore AS:石油・ガス:M&Aディール及び事業提携情報
    Summary Ross Offshore AS (Ross Offshore) is an oilfield service provider that provides project management and consultancy services. The company provides drilling and well, late life operation, subsurface, ross operations, HSEQ, consultancy services, and others. It offers late life operation services …
  • eNeura Inc:医療機器:M&Aディール及び事業提携情報
    Summary eNeura Inc (eNeura) formerly eNeura Therapeutics LLC is a medical device manufacturing company that offers portable, non-invasive transcranial magnetic stimulation devices for treating migraine. The company offers products such as flagship product and eNeura Spring TMS device, among others. …
  • Asseco Poland SA (ACP):企業の財務・戦略的SWOT分析
    Summary Asseco Poland SA (Asseco) is a technology company that offers information processing solutions. The company offers banking, insurance companies, public institutions, healthcare, telecommunication, utilities, ERP solutions, IT infrastructure and others. Its IT infrastructure solutions include …
  • Koninklijke Ahold Delhaize N.V.:戦略・SWOT・企業財務分析
    Koninklijke Ahold Delhaize N.V. - Strategy, SWOT and Corporate Finance Report Summary Koninklijke Ahold Delhaize N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Per Aarsleff Holding AS (PAAL B):企業の財務・戦略的SWOT分析
    Per Aarsleff Holding AS (PAAL B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Spinal Elements Inc:医療機器:M&Aディール及び事業提携情報
    Summary Spinal Elements Inc (Spinal Elements), formerly Quantum Orthopedics Inc, a subsidiary of Spinal Elements, is a medical device manufacturing company that manufactures spinal implants and instruments. The company provides products such as cervical implant systems, anterior cervical plate syste …
  • Asseco Poland SA (ACP):企業の財務・戦略的SWOT分析
    Summary Asseco Poland SA (Asseco) is a technology company that offers information processing solutions. The company provides products such as proprietary software and services, third party software and services; and hardware and infrastructure. Asseco also offers services that include cloud services …
  • Desktop Genetics Ltd-医療機器分野:企業M&A・提携分析
    Summary Desktop Genetics Ltd (DeskGen) is a provider of genome editing solutions. The company offers software solutions for the design, synthesis and assembly of DNA. It offers deskgen, which is a software system that helps scientists to organize, optimize, and automate their research. DeskGen’s CRI …
  • Spectris Plc (SXS):企業の財務・戦略的SWOT分析
    Spectris Plc (SXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆